Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Genmab A/S is a Danish biotechnology company focused on the discovery, development, and commercialization of differentiated antibody-based therapies for the treatment of cancer and other serious diseases. The company operates within the biopharmaceutical and oncology industries, with a business model that combines internal research and development with strategic partnerships with large pharmaceutical companies. Genmab’s revenue is primarily driven by royalties from marketed antibody medicines, milestone payments, and collaborative research agreements, supplemented by direct product sales from co-commercialized therapies.
Founded in 1999, Genmab has evolved from a research-focused antibody discovery company into a globally recognized oncology innovator with multiple approved medicines and a deep clinical pipeline. Its strategic advantage lies in its proprietary antibody technologies, including next-generation bispecific and effector-enhanced antibodies, as well as a capital-efficient model that leverages partners for late-stage development and commercialization while retaining meaningful long-term economics.
Business Operations
Genmab’s operations are organized around research and early-to-late-stage clinical development of antibody therapeutics, with revenue generated through collaboration agreements, royalty income, and co-commercialization activities. Key marketed products associated with Genmab’s technology include DARZALEX® (daratumumab) and DARZALEX FASPRO®, developed with Janssen Biotech, as well as TEPEZZA® (teprotumumab), originally developed with Horizon Therapeutics, now part of Amgen. These products represent the majority of the company’s recurring royalty income.
The company conducts R&D internally while relying on partners for manufacturing, regulatory approval, and global sales infrastructure. Genmab controls a suite of proprietary platforms, including DuoBody®, HexaBody®, and DuoHexaBody® technologies. It operates through wholly owned subsidiaries, including Genmab BV, Genmab US, Inc., and Genmab K.K., which support research, clinical development, and corporate functions across regions.
Strategic Position & Investments
Genmab’s strategy centers on expanding its clinical-stage oncology pipeline while selectively advancing programs toward commercialization either independently or with partners. Growth initiatives focus on bispecific antibodies, antibody-drug conjugate combinations, and immune effector modulation, particularly in hematologic malignancies and solid tumors. The company consistently reinvests royalty-derived cash flows into R&D to sustain long-term innovation.
Major strategic transactions include Genmab’s long-standing collaboration with Johnson & Johnson for daratumumab-based therapies and its acquisition of ProfoundBio in 2024, which expanded Genmab’s capabilities in antibody-drug conjugates (ADCs). The company does not operate a large venture investment arm but maintains a concentrated portfolio of wholly owned and partnered clinical assets aligned with its oncology focus.
Geographic Footprint
Genmab is headquartered in Copenhagen, Denmark, and maintains a significant presence in Europe and North America, which together represent its primary operational and strategic regions. The company’s U.S. operations, centered in New Jersey and California, support clinical development, regulatory affairs, and alliance management, while European operations anchor research and corporate leadership.
Through its partners, Genmab’s medicines are marketed globally, with commercial reach across North America, Europe, Asia-Pacific, and other international markets. Although Genmab does not maintain large-scale manufacturing facilities, its technologies underpin products sold worldwide, giving the company substantial international economic exposure through global royalty streams.
Leadership & Governance
Genmab is led by an experienced executive team with deep expertise in biotechnology R&D, oncology drug development, and global partnerships. The leadership emphasizes a science-driven culture, disciplined capital allocation, and long-term value creation through innovation and strategic collaboration.
Key executives include:
- Jan van de Winkel – Chief Executive Officer
- Torbjørn Grubb – Chief Financial Officer
- Louise Ødum – Executive Vice President, Research & Development
- Erik Randløv Jørgensen – Executive Vice President & Chief Legal Officer
- Signe Kirk Pedersen – Executive Vice President, People & Organization
The company operates under a one-tier board structure consistent with Danish corporate governance standards, with strong oversight of risk management, R&D investment, and alliance strategy.